Furthermore, inhibiting HO-1 has been shown to enhance the efficacy of certain cancer treatments in PC, suggesting that HO-1 inhibition may improve the overall immune response against PC and increase the effectiveness of other therapies [129]. The gene discussed is HMOX1; the disease is pachyonychia congenita.